Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of Oral LY3493269 in Healthy Participants
NCT04682106Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2021
- Primary completion
- Nov 2021
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LY3493269 in type 2 diabetes mellitus (T2DM) and obesity (5 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants With One or More Treatment-Emergent Adverse Events. Started May 2021; status: completed.
02
Drugs
LY3493269
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT04682106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04682106.